Abstract: Provided are an anti-B7H3 antibody and the use thereof. A variable region of the antibody comprises amino acid sequences as shown in SEQ ID NOs: 25-39. The anti-B7H3 antibodies 26B6, 6F7, 2B8, and 23H1 have a significant binding capability to B7H3, can not only bind to purified or free B7H3 protein, but also can bind to B7H3 protein on a cell surface; and after humanized modification, the affinity between the antibody and B7H3 is further improved, and the antibody has important application prospects in clinical diagnosis and/or treatment of B7H3-positive tumors.

Abstract: Methods for constructing an ADR prediction model for elderly patients, a prediction system, and/or a storage medium are disclosed. The method includes constructing ADR trigger entries for elderly patients; based on the ADR trigger entries for elderly patients, combining evidence-based evaluation results to construct a dataset of risk factors related to ADRs in elderly patients; completing the annotation of risk factors and ADR discrimination for the dataset related to ADRs in elderly patients; using the annotated dataset information to train a machine learning model, so as to obtain an ADR risk prediction model for elderly patients. A prediction system utilizing the ADR prediction model for elderly patients is constructed.

Abstract: Provided is a chimeric antigen receptor targeting CLL1 and an application thereof. The chimeric antigen receptor targeting CLL1 comprises an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain; the antigen binding domain is an anti-CLL1 antibody. The present application uses an anti-CLL1 antibody as the antigen binding domain to construct a chimeric antigen receptor molecule, the chimeric antigen receptor targeting CLL1 has specific targeting effect on CLL1 positive tumor cells, and immune cells expressing chimeric antigen receptor targeting CLL1 have a significant killing effect in vitro and in vivo, and secrete a large amount of cytokine IFN-? after co-cultured with CLL1 positive tumor cells, which has a specific clearance effect on CLL1 positive tumor cells.

Abstract: The present invention relates to LPA-targeting siRNA and a conjugate, and specifically relates to LPA-targeting siRNA, a siRNA conjugate, a composition, and a pharmaceutical use thereof. The present invention also relates to a pharmaceutical composition, a cell or a kit comprising the siRNA, and a method for the siRNA and the siRNA conjugate for treating and/or preventing related disorders suffered by a subject.

Abstract: An apparatus, method, and computer-readable storage medium for magnetron sputtering for thin film deposition. The apparatus may include a chamber for thin film deposition, configured to house a target configured to be held by a target holder, and a pedestal configured to support a substrate, and arranged opposite to the target; a magnetron configured to generate a magnetic field around a surface of the target, for electron confinement, and to facilitate ignition and maintenance of plasma; a main power supply, configured to apply power to the target to form an electrical field, the electrical and magnetic fields can convert at least a part of working gas into the plasma, and the electrical field can direct a part of ions in the plasma toward the target; and a resistance measurement meter in electrically connection with each of an electrical ground point and the target, and configured to measure a resistance therebetween.

Abstract: An alkali metal monohydrogen cyanurate compound of the chemical formula AM(HC3N3O3)·nH2O (specifically such as KLi(HC3N3O3)·2H2O, RbLi(HC3N3O3)·2H2O, RbNa(HC3N3O3)·2H2O) and a nonlinear optical crystal thereof are related to optoelectronic functional materials. Measured using a powder frequency doubling test method, and the powder frequency doubling effect of the nonlinear optical crystal is about 2-3 times that of KH2PO4 (KDP). The ultraviolet absorption edge of the nonlinear optical crystal is shorter than 250 nm. The nonlinear optical crystal can achieve the harmonic generator of double, triple, or quadruple frequency for Nd: YAG (?=1.064 ?m). Moreover, the nonlinear optical crystal is of a single crystalline structure, is colorless and transparent, and does not deliquesce in air.

Abstract: Methods and systems for data management optimization are disclosed. The methods involve retrieving at least one of data querying instructions or data generating paths, and constructing knowledge graphs to visualize data structure within the data objects. Data objects are matched to determine similarities among the knowledge graphs. Cost functions determined by the similarities generate costs to evaluate aspects of the data objects, which are then ranked to inform data processing workflows within the data management system. This disclosure improves data handling efficiency and operational performance.

Abstract: Methods for constructing an ADR prediction model for elderly patients, a prediction system, and/or a storage medium are disclosed. The method includes constructing ADR trigger entries for elderly patients; based on the ADR trigger entries for elderly patients, combining evidence-based evaluation results to construct a dataset of risk factors related to ADRs in elderly patients; completing the annotation of risk factors and ADR discrimination for the dataset related to ADRs in elderly patients; using the annotated dataset information to train a machine learning model, so as to obtain an ADR risk prediction model for elderly patients. A prediction system utilizing the ADR prediction model for elderly patients is constructed.

Abstract: Provided is an anti-CLL1 antibody and an application thereof. The variable region of the anti-CLL1 antibody includes the CDRs of SEQ ID NO: 1 to 6, SEQ ID NO: 5, and SEQ ID NO: 7 to 11 or SEQ ID NO: 12 to 17. The anti-CLL1 antibody of the present application has significant binding ability to both free and cell surface CLL1. After humanization, the affinity of the antibody to CLL1 is further improved, and it has important application prospect in the clinical diagnosis and/or treatment of tumors.

Abstract: The present disclosure relates to the field of biomedicine, in particular, to a CD300LD inhibitor and use thereof in the preparation of tumor immunotherapy products. In the present disclosure, the CD300LD inhibitor regulates the migration and function of PMN-MDSC cells by modulating S100A8/A9 in its downstream signaling pathway, and plays an important role in the establishment of the tumor microenvironment. The polypeptide isolated by the present disclosure is used as a CD300LD inhibitor, and CD300LD-ECD protein can inhibit CD300LD by competitive binding, thus inhibiting tumor development. When tumor-bearing mice are treated with this peptide, the development of tumors can be significantly inhibited. In addition, CD300LD-ECD has a significant anti-tumor synergistic effect with PD1 antibody.

Abstract: This invention belongs to the field of preparation of macromolecule sample of various volumes, pertaining to a detergent-mixed dry hydrogel particle and a method of using the particle to mass concentrate the macromolecule liquid sample or to enhance specific activity of the protein liquid sample. After thorough suspension and hydration in a detergent solution, the hydrogel particle is separated from the excess of the detergent solution and dried into the detergent-mixed dry hydrogel particle; upon contacting the macromolecule liquid sample in certain ratio with the dry particle having a pore size of its cross-linked network smaller than the macromolecule to allow absorption and swelling of the hydrogel particle, filter centrifugation or filter conical rotating drum centrifugation is exercised to remove the hydrogel particle whose surface is deprived of water and to collect the concentrate filtrate of the macromolecule mass or the protein sample with enhanced specific activity.

Abstract: Provided are an anti-B7H3 antibody and the use thereof. A variable region of the antibody comprises amino acid sequences as shown in SEQ ID NOs: 25-39. The anti-B7H3 antibodies 26B6, 6F7, 2B8, and 23H1 have a significant binding capability to B7H3, can not only bind to purified or free B7H3 protein, but also can bind to B7H3 protein on a cell surface; and after humanized modification, the affinity between the antibody and B7H3 is further improved, and the antibody has important application prospects in clinical diagnosis and/or treatment of B7H3-positive tumors.

Abstract: Methods and devices for encrypting Network Configuration Protocol (NETCONF) datastore in communication networks are disclosed. One of the methods is performed by a device using NETCONF. The method comprises enabling a function for NETCONF Datastore Security (DS-SEC). The method further comprises publishing a first indication indicating that the device supports the NETCONF DS-SEC function.

Abstract: A data processing method based on simultaneous interpretation, applied to a server in a simultaneous interpretation system, including: obtaining audio transmitted by a simultaneous interpretation device; processing the audio by using a simultaneous interpretation model to obtain an initial text; transmitting the initial text to a user terminal; receiving a modified text fed back by the user terminal, the modified text being obtained after the user terminal modifies the initial text; and updating the simultaneous interpretation model according to the initial text and the modified text.

Abstract: An siRNA targeting 170-hydroxysteroid dehydrogenase type 13 and a siRNA conjugate. Also disclosed are a pharmaceutical composition, cell or kit containing the siRNA, and a method for using the siRNA for the treatment and/or prevention of subjects suffering from HSD17B13-related disorders (such as chronic fibroinflammatory liver disease).

Abstract: A method for speech recognition based on language adaptivity comprises obtaining voice data of a user. The method also comprises extracting, based on the obtained voice data, a phoneme feature representing pronunciation phoneme information. The phoneme feature is input to a pre-trained language discrimination model that is pre-trained based on a multilingual corpus. A language discrimination result corresponding to the phoneme feature and in accordance with the language discrimination model is obtained. The method also comprises obtaining a speech recognition result of the voice data based on a language acoustic model of a language corresponding to the language discrimination result. The method further comprises determining a speech recognition result of the voice data based on a language acoustic model of a language corresponding to the language discrimination result.

Abstract: A chassis for an edge device includes a cabinet and a heat exchange component. The heat exchange component is disposed in a space enclosed by the cabinet. The space in the cabinet is divided into a first space and a second space for placement an electronic device. The heat exchange component performs heat transfer between the first space and the second space. A first air inlet and a first air outlet are disposed in the first space, and an airflow entering from the first air inlet flows through a first surface of the heat exchange component and exits from the first air outlet.

Abstract: A chimeric antigen receptor fusion protein co-expressing IL-7 and CCR2b, and application thereof are provided. The fusion protein includes a chimeric antigen receptor, a 2A peptide, IL-7, a 2A peptide and CCR2b which are sequentially linked in series.

Abstract: Provided are an anti-B7H3 chimeric antigen receptor and an application thereof. The anti-B7H3 chimeric antigen receptor comprises an antigen binding domain, a hinge region, a transmembrane domain and a signaling transfer structural domain. The antigen binding domain is an anti-human B7H3 antibody. The anti-B7H3 chimeric antigen receptor has a specific targeting effect on B7H3-positive tumor cells, T cells that express the anti-B7H3 chimeric antigen receptor have significant killing effects in vitro and in vivo, can effectively remove the B7H3-positive tumor cells, and having important significance in the field of tumor therapy.